Sugi Predict

Sugi Predict / Targets / ALKBH3

ALKBH3

Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 · Q96Q83 · ALKBH3 on Sugi Atlas →

4,478 patent compounds predicted against ALKBH3, 2,503 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2564163 SCHEMBL2564163 0.56 15/20
SCHEMBL2567565 SCHEMBL2567565 0.42 12/20
SCHEMBL5178964 SCHEMBL5178964 0.58 10/20
SCHEMBL5058661 SCHEMBL5058661 0.52 10/20
SCHEMBL2571554 SCHEMBL2571554 0.56 9/20
SCHEMBL2714869 SCHEMBL2714869 0.53 9/20
SCHEMBL3113740 SCHEMBL3113740 0.43 9/20
SCHEMBL2569372 SCHEMBL2569372 0.61 8/20
SCHEMBL2877411 SCHEMBL2877411 0.48 8/20
SCHEMBL2226023 SCHEMBL2226023 0.48 8/20
SCHEMBL2570816 SCHEMBL2570816 0.45 8/20
SCHEMBL3125409 SCHEMBL3125409 0.41 8/20
SCHEMBL4895300 SCHEMBL4895300 1.00 7/20
SCHEMBL2716237 SCHEMBL2716237 0.50 7/20
SCHEMBL3046881 SCHEMBL3046881 0.49 7/20
SCHEMBL2567480 SCHEMBL2567480 0.47 7/20
SCHEMBL2568228 SCHEMBL2568228 0.47 7/20
SCHEMBL3112565 SCHEMBL3112565 0.46 7/20
SCHEMBL4612998 SCHEMBL4612998 0.46 7/20
SCHEMBL5215154 SCHEMBL5215154 0.45 7/20

Clinical trials — most relevant to ALKBH3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis PHASE2UNKNOWN
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy PHASE2SUSPENDED
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC PHASE2COMPLETED
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas PHASE2COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
The Role of FTO Gene Polymorphism and Insulin Preparation in Obesity in Children With Type 1 Diabetes Mellitus nanCOMPLETED
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU) nanRECRUITING
Association Between the Change of the Genes With Hormones and Food Consumption of Obese nanCOMPLETED
A Pilot Study on ALK Gene Mutations in Neuroblastoma nanUNKNOWN
Proof of Concept Creatine Supplementation for Homocystinuria Study nanACTIVE_NOT_RECRUITING
Prognosis of METTL-14 in Endometrial Carcinoma nanNOT_YET_RECRUITING
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Immune and Genomic Markers in ALK+ NSCLC nanACTIVE_NOT_RECRUITING
Using the Epitranscriptome to Diagnose and Treat Gliomas nanRECRUITING
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma nanNOT_YET_RECRUITING
Molecular Profiling for Risk Stratification in Appendiceal Cancer nanRECRUITING
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ALKBH3 binder may also engage these)

ProteinNameSimilarity
Q8K1E6 — 1.000 Q8K1E6 →
Q32L00 — 1.000 Q32L00 →
Q5XIC8 — 0.999 Q5XIC8 →
ALKBH2 DNA oxidative demethylase ALKBH2 0.989 landscape →
Q6P6J4 — 0.986 Q6P6J4 →
Q58DM4 — 0.986 Q58DM4 →
Q2UMQ5 — 0.986 Q2UMQ5 →
Q6C710 — 0.985 Q6C710 →
A4H7G5 — 0.985 A4H7G5 →
Q7S9B6 — 0.985 Q7S9B6 →
C8VBH4 — 0.984 C8VBH4 →
Q65143 — 0.984 Q65143 →
KAT8 Histone acetyltransferase KAT8 0.984 landscape →
Q4IEV4 — 0.984 Q4IEV4 →
Q8RXN5 — 0.984 Q8RXN5 →
Q4QFY1 — 0.984 Q4QFY1 →
Q19546 — 0.984 Q19546 →
Q6C7U7 — 0.983 Q6C7U7 →
C8VJR5 — 0.983 C8VJR5 →
Q5XI06 — 0.983 Q5XI06 →
Q7F2E4 — 0.983 Q7F2E4 →
A5E032 — 0.983 A5E032 →
A1Z830 — 0.983 A1Z830 →
P0C8H0 — 0.983 P0C8H0 →
P12438 — 0.983 P12438 →
P0C8H1 — 0.983 P0C8H1 →
Q9USM5 — 0.983 Q9USM5 →
Q8BJM7 — 0.983 Q8BJM7 →
F4IF36 — 0.983 F4IF36 →
Q4E409 — 0.982 Q4E409 →